FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 384 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Young Tulsa Mom Grows Closer To Her Own Mom During Almost... May 10, 2019 New on NCI Websites for July 2019 July 2, 2019 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma September 8, 2023 Load more HOT NEWS Trial Establishes Preferred Treatment for Some People with Esophageal Cancer No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy... What’s happened to cancer clinical trials during the COVID-19 pandemic? Interactive App Improves Colorectal Cancer Screening Rates
